Media headlines about Perrigo (NYSE:PRGO) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Perrigo earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.1305585637274 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Perrigo Company (PRGO) Stock Rating Reaffirmed by Stifel Nicolaus (americanbankingnews.com)
- Perrigo (PRGO) to Sell Active Pharmaceutical Ingredients Business to SK Capital – StreetInsider.com (streetinsider.com)
- Parnassus Investments /ca Sold A Lot More Perrigo Company plc Ordinary Sh (PRGO) Stock Last Quarter – Modern Readers (modernreaders.com)
- Perrigo Co. shares surge 12% after Q2 profit, revenue beats – MarketWatch (marketwatch.com)
- Perrigo Company plc Ordinary Sh (PRGO) Ownership Decreased by Parnassus Investments /ca – Modern Readers (modernreaders.com)
PRGO has been the topic of a number of research reports. Goldman Sachs Group, Inc. (The) upgraded Perrigo from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $66.00 to $79.00 in a report on Friday. Royal Bank Of Canada reiterated a “hold” rating and set a $66.00 target price on shares of Perrigo in a report on Wednesday, May 24th. Deutsche Bank AG reiterated a “buy” rating and set a $88.00 target price (up from $86.00) on shares of Perrigo in a report on Monday, July 17th. Canaccord Genuity set a $86.00 target price on Perrigo and gave the company a “buy” rating in a report on Monday, May 22nd. Finally, Cantor Fitzgerald began coverage on Perrigo in a research note on Friday, June 16th. They set an “overweight” rating and a $85.00 price objective for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Perrigo currently has an average rating of “Hold” and an average price target of $85.31.
Shares of Perrigo (PRGO) traded up 2.15% during mid-day trading on Friday, reaching $78.49. The company’s stock had a trading volume of 3,098,187 shares. Perrigo has a 12 month low of $63.68 and a 12 month high of $99.14. The firm’s market capitalization is $11.25 billion. The company has a 50 day moving average of $73.59 and a 200-day moving average of $73.05.
Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, August 10th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.28. Perrigo had a positive return on equity of 11.37% and a negative net margin of 51.04%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the prior year, the business earned $1.93 EPS. The business’s revenue for the quarter was down 7.7% compared to the same quarter last year. Equities research analysts forecast that Perrigo will post $4.32 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Friday, August 25th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.82%. The ex-dividend date is Wednesday, August 23rd. Perrigo’s dividend payout ratio is -3.51%.
COPYRIGHT VIOLATION WARNING: “Perrigo (NYSE:PRGO) Earns News Sentiment Rating of 0.12” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-perrigo-nyseprgo-share-price-updated-updated.html.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.